COMBOGESIC IV

Growth

acetaminophen and ibuprofen injection

NDAINTRAVENOUSSOLUTION

Approved

Oct 2023

Lifecycle

Growth

Competitive Pressure

0/100

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (2)

moderate to severe pain less

Loss of Exclusivity

LOE Date

Jan 14, 2036

120 months away

Patent Expiry

Jan 14, 2036

Exclusivity Expiry

Oct 17, 2026

Patent Records (5)

Patent #	Expiry	Type	Use Code
11446266	Oct 26, 2031		U-3745
11896567	Oct 26, 2031		U-3745
12220392	Oct 26, 2031		U-4307
11389416	Jul 17, 2035	Product	—
12083087	Jul 17, 2035		U-3745

Company

NJ - Berkeley Heights

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers